Indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older.
Fluticasone propionate is a glucocorticoid with high topical anti-inflammatorypotency, but a low HPA-axis suppressive activity after dermal administration. It, therefore, has a therapeutic index which is greater than most of the commonly available steroids. Fluticasone propionate has a high degree of selectivity for the glucocorticoid receptor. In vitro studies show that fluticasone propionate has a strong affinity for, and agonist activity at, human glucocorticoid receptors. This receptor is believed to be responsible for the anti-inflammatory properties of glucocorticoids. Fluticasone propionate has weak affinity forthe progesterone receptor, andvirtually no affinity for the mineralocorticoid, estrogen, or androgen receptors. The therapeutic potency of glucocorticoids is related to the half-life of the glucocorticoid-receptor complex. The half-life of the Fluticasone propionate glucocorticoid-receptor complex is approximately 10 hours.
NASAL Treatment & prophylaxis of allergic rhinitis: Adult: 100 mcg into each nostril once daily, increased to 100 mcg bid. Child: >4 yr: 50 mcg into each nostril once daily, increased to 50 mcg bid. Nasal polyps: Adult: As propionate: 200 mcg to be instilled into each nostril 1-2 times daily for at least 4-6 wk. INHALATION Asthma prophylaxis: Adult: As powd or aerosol: 100-250 mcg bid in mild cases, up to 500-1000 mcg bid in severe cases. Child: As powd or aerosol: >4 yr: Initially, 50-100 mcg bid. May increase to 200 mcg, if necessary. Severe asthma: Adult: As nebuliser: 0.5-2 mg bid. Child: As nebuliser: 4-16 yr: 1 mg bid. Chronic obstructive pulmonary disease: Adult: As powd or aerosol: 500 mcg bid. TOPICAL/CUTANEOUS Corticosteroid-responsive dermatoses: Adult: As propionate: Apply a 0.05 or 0.005% cream/ointment onto affected area.
No information is available.
Hypersensitivity. Acne vulgaris, rosacea, perioral dermatitis, skin atrophy; hypersensitivity. Primary cutaneous viral infections (e.g. herpes simplex, chicken pox), perianal & genital pruritus, primary fungal or bacterial skin infections. Inhalation: Status asthmaticus. Children, pregnancy, lactation, concomitant skin infections. Concomitant skin/lung/systemic infections. Advised to rinse mouth w/ water every time after inhalation. Application to large areas, broken skin or under occlusive dressings.
Topical: Pruritus, hypertrichosis, dryness, numbness of fingers, burning, eruptions, hypopigmentation, allergic contact dermatitis, secondary infection, skin atrophy, Cushing’s syndrome,reversible HPA-axis suppression. Inhalation: Oropharyngeal candidiasis, pharyngitis, dysphoria, cough, rhinitis, nasal congestion & headache. Systemic absorption may be seen when applied to large areas, when skin is broken or under occlusive dressings. Suppression of immune system.
The safety of fluticasone propionate when taken during pregnancy. Asthma affects many women during pregnancy and asthma treatment guidelines highlight the importance of maintaining good asthma control during pregnancy, with inhaled corticosteroids (ICS) recommended as first line treatment. Although not measured, the amounts of inhaled corticosteroids absorbed into the maternal bloodstream and excreted into breastmilk are probably too small to affect a breastfed infant. Reviewers and an expert panel consider inhaled corticosteroids acceptable to use during breastfeeding.
Acute overdosage is very unlikely to occur, however, in case of chronic overdosage or misuse the features of hypercorticism may appear, and in this situation, as with any corticosteroid, the application should be discontinued. Overdosage by ingestion of fluticasone propionate cream or ointment is extremely unlikely to occur due to the very low oral bioavailability of fluticasone propionate.
Store below 30°C.Do not freeze.
.png&w=384&q=75)